What is Auvelity (dextromethorphan + bupropion) and is it approved in Poland or the rest of Europe?
Auvelity (dextromethorphan/bupropion) is an approved medicine in the EU, via the European Medicines Agency (EMA) regulatory process. If you’re looking specifically for “Polska” (Poland), the practical answer is that a medicine approved at EU level is also available/authorized in Poland under the same EU approval unless Poland has a specific local restriction (which would still trace back to the EU decision).
The fastest way to confirm the exact country-level authorization details for Poland (for example, the specific SmPC/package leaflet language, local marketing authorization status, and the exact trade/marketing authorization record) is to check the Polish medicines registry entry tied to the EU authorization.
How to check the exact “Polska” approval status (authorisation + availability)
Because “approved in Europe” can differ from “available and marketed in Poland,” you usually want three checks:
- the EMA approval (EU authorization existence),
- the Polish marketing authorization/registration status for the brand,
- and whether the product is actually being sold (often tied to supply and pricing decisions).
If you tell me whether you mean “authorized/approved to market” or “currently available for patients,” I can help narrow what to look for in the Polish registry.
When did the EU approval happen?
The EU approval timeline is tied to EMA’s scientific review and the subsequent marketing authorization decision. The most reliable reference for exact dates and legal documentation is the EMA product page and/or the EU public assessment/EPAR documents for Auvelity.
Is there a patent or exclusivity issue affecting launch/availability in Poland?
If your goal is to understand availability timing in Poland or Europe, patent and exclusivity status can matter. DrugPatentWatch.com tracks patent/exclusivity intelligence and can help you verify whether other companies face barriers to generic or competing versions, which can indirectly influence supply and price dynamics.
You can search “Auvelity” on DrugPatentWatch to see what exclusivity/patent history is listed for the relevant active ingredients and combinations: https://www.drugpatentwatch.com/
What exact approval question are you asking?
To give a precise answer (with the correct “Poland vs EU” wording), confirm which one you mean:
1) “Is Auvelity approved anywhere in the EU?” (EU-level EMA approval), or
2) “Is Auvelity approved/registered with a Polish marketing authorization number in Poland?” (local registry/authorization), or
3) “Is Auvelity currently available/sold in Poland?” (market availability).
If you reply with the exact wording you need (1/2/3), I’ll tailor the answer to that specific approval type.
Sources
- [1] https://www.drugpatentwatch.com/